Clinical trials: Neoplasm Recurrence
Kidney Cancer, Renal Cancer
Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants
A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer
- Trial name
- NCT03568435
- Testing
- Non-Interventional
- Where
- Japan
- Volunteers
- 212 people
- Sponsor
- Bristol-Myers Squibb
Rectal Cancer, Surgery
Assessment of Functional Digestive and Genitourinary Outcomes in Patients With Rectal Cancer.
Total mesorectal excision and neoadjuvant radio-chemotherapy have revolutionized the management of rectal cancer allowing an increase in survival (between 55 and 68% at 5 years) and allowing a decrease of local recurrence (under…
- Trial name
- Rectqol (NCT03459235)
- Testing
- quality of life
- Where
- France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Caen
Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma
Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing melphalan directly to the tumor may kill more tumor cells and cause less damage to healthy tissues.
- Conditions
- Stage IVB Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
- Trial name
- NCT00019968
- Testing
- melphalan, tumor necrosis factor
- Sponsor
- National Institutes of Health Clinical Center (CC)
HER2-positive Breast Cancer, Male Breast Cancer
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00039455
- Testing
- trastuzumab, alvocidib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Bone Metastases
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT00040755
- Testing
- rebimastat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087126
- Testing
- topotecan hydrochloride
- Where
- 27 sites in United States
- Volunteers
- 27 people
- Sponsor
- Gynecologic Oncology Group
Non-small Cell Lung Cancer
Special Drug Use-results Surveillance of Tabrecta Tablets
This study was an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance.
- Trial name
- NCT04575025
- Testing
- Tabrecta tablets
- Where
- 78 sites in Japan
- Volunteers
- 109 people
- Sponsor
- Novartis Pharmaceuticals
Internal Hemorrhoid
Recurrence Rate of Minimally Invasive Endoscopic Treatment of Internal Hemorrhoids
2.1 Main objective: To observe the short-term and long-term recurrence rates of various endoscopic minimally invasive treatment methods for internal hemorrhoids and different time points of endoscopic minimally invasive treatment…
- Trial name
- NCT06250140
- Testing
- Tie up device
- Volunteers
- 900 people
- Sponsor
- Shenzhen Hospital of Southern Medical University
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of CPI-613 when given together with bendamustine hydrochloride in treating patients with relapsed or refractory T-cell non-Hodgkin lymphoma or Hodgkin lymphoma.
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT02168140
- Testing
- 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer
The purpose of this study is to determine the maximum tolerated dose of veliparib that can be given while a patient is receiving radiation therapy.
- Trial name
- NCT01477489
- Testing
- Veliparib, Standard radiation treatment
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Michigan Rogel Cancer Center
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Continuous treatment until progression or occurence of intolerable Adverse Event (AE) or end of trial. The end of trial is one year after the last patient has entered the study.
- Trial name
- NCT02514174
- Testing
- Afatinib
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
- Trial name
- PRESERVE (NCT07898774)
- Testing
- Pegcetacoplan
- Where
- 33 sites in Brazil, Canada and 8 more
- Volunteers
- 30 people
- Sponsor
- Swedish Orphan Biovitrum
Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
This phase II trial studies how well venetoclax and ibrutinib work in treating patients with chronic or small lymphocytic leukemia.
- Conditions
- Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT02756897
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Venetoclax
- Where
- United States
- Volunteers
- 234 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of TK216 and decitabine when given together in treating patients with acute myeloid leukemia that has come back or does not respond to treatment.
- Trial name
- NCT03752138
- Testing
- Group 1: TK216, Group 2: TK216, Part 2: Decitabine 10mg/m2
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
This phase II trial studies how well copanlisib works in treating patients with endometrial cancer that has not decreased or disappeared, and the cancer may still be in the body despite treatment (persistent) or has come back…
- Conditions
- Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT02728258
- Testing
- Copanlisib, Laboratory Biomarker Analysis
- Where
- 43 sites in United States
- Volunteers
- 11 people
- Sponsor
- NRG Oncology
Ovarian Cancer Recurrent
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial benefit/risk of paclitaxel combined with EP-100 can be studied.
- Trial name
- ESP2011-002 (NCT01485848)
- Testing
- EP-100, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Esperance Pharmaceuticals Inc
Cancer, Non Small Cell Lung Cancer
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
This exploratory clinical study is designed to obtain pre-therapeutic imaging assessments using positron emission tomography (PET) imaging in 21 patients with Stage IIIB/IV or recurrent non-small cell lung cancer (NSCLC) and an…
- Trial name
- NCT00708448
- Testing
- PET Imaging, Erlotinib, Bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006115
- Testing
- FOLFIRI regimen, FOLFOX regimen, fluorouracil
- Where
- 16 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Relapsed or Refractory Multiple Myeloma
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D[s]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with…
- Trial name
- NCT06604715
- Testing
- JNJ-87562761
- Where
- 15 sites in Canada, South Korea and 2 more
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
Relapsing-Remitting Multiple Sclerosis
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
The aim of the study is to determine whether a therapeutic strategy combining mitoxantrone and interferon beta1b can delay disease progression of at least one point on EDSS scale in patients with clinically very active…
- Trial name
- NCT00219908
- Testing
- Mitoxantrone
- Where
- 23 sites in France, Italy
- Volunteers
- 124 people
- Sponsor
- Rennes University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.